• Aurora Cannabis (ACB) has announced a lineup of cannabis products set to roll out in October
  • New flower products include three unique and proprietary strains from Aurora’s esteemed breeding program: Electric Honeydew, Ultra Grape Kush and Organic BC White Grape OG
  • Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets
  • Aurora Cannabis Inc. (ACB) is up 6.99 per cent, trading at C$1.53 per share at 2:03 pm ET

Aurora Cannabis (ACB) has announced a lineup of cannabis products set to roll out in October.

New flower products include three unique and proprietary strains from Aurora’s esteemed breeding program: Electric HoneydewUltra Grape Kush and Organic BC White Grape OG.

Aurora’s best-in-class genetics breeding program, backed by extensive consumer research and development, was the catalyst for the company’s most robust product release in over two years. The company continues to focus on expanding its premium product offerings and developing unique cultivars and formats that appeal to a wide variety of consumer and patient tastes.

In the last 16 months, the company has commercialized 12 original cultivars under its various consumer brands. Starting this month, Aurora patients will have access to the largest-ever selection of products and formats on Aurora Medical.

Alongside more than 60 new products on the channel will be Aurora’s full portfolio of adult-use cannabis brands. It will include Being Quickstrips, Greybeard premium flower, a wider selection of pre-rolls, new concentrates such as hash and live resin diamonds and sauce, and a new offering of minor cannabinoid (CBN) oils.

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets.

Aurora Cannabis Inc. (ACB) is up 6.99 per cent, trading at C$1.53 per share at 2:03 pm ET.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.